Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653121 | 0.91 | FGFR1 (0.43) | FGFR1IDO1HPGDSRCNCOA3 | |
| SCHEMBL2646511 | 0.89 | HPGD (0.47) | FGFR1IDO1HPGDNCOA3ALDH1A1 | |
| SCHEMBL2655096 | 0.89 | SMN1; SMN2 (0.42) | FGFR1IDO1HPGDSRCALDH1A1 | |
| SCHEMBL2656896 | 0.87 | FGFR1 (0.45) | FGFR1IDO1HPGDSRCALDH1A1 | |
| SCHEMBL2653789 | 0.87 | IDO1 (0.42) | FGFR1IDO1HPGDSRCNCOA3 | |
| SCHEMBL2662404 | 0.84 | FGFR1 (0.38) | FGFR1IDO1HPGDSRCALDH1A1 | |
| SCHEMBL2659275 | 0.81 | FGFR1 (0.39) | FGFR1IDO1HPGDSRC | |
| SCHEMBL2647252 | 0.80 | FGFR1 (0.62) | FGFR1IDO1HPGDNCOA3ALDH1A1 | |
| SCHEMBL2660047 | 0.80 | HPGD (0.48) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2656192 | 0.80 | IDO1 (0.49) | FGFR1IDO1HPGDNCOA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | claimed |
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | FGFR1 3374/4885IDO1 1002/4885HPGD 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.